Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Grace Therapeutics Inc GRCE

Healthcare Biotechnology
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a... see more

Recent & Breaking News (NDAQ:GRCE)

Acasti Pharma to Report First Quarter 2023 Financial Results on Thursday, August 11, 2022

GlobeNewswire August 2, 2022

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company's Drug Candidate for the Treatment of Postherpetic Neuralgia

GlobeNewswire July 27, 2022

Acasti Pharma Inc. Discusses Year-End Results and Clinical Development Progress with The Stock Day Podcast

Newsfile July 7, 2022

Acasti Pharma Announces Annual Grants of Performance Stock Options

GlobeNewswire June 22, 2022

Acasti Pharma Reports Fiscal Year 2022 Operational Results

GlobeNewswire June 21, 2022

Acasti Pharma Schedules Fiscal Year 2022 Business Update Conference Call

GlobeNewswire June 16, 2022

Acasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101

GlobeNewswire June 14, 2022

Acasti Pharma Inc. Retains Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program

PR Newswire May 23, 2022

Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints

GlobeNewswire May 18, 2022

Update: Acasti Pharma CEO to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 18th

ACCESS Newswire May 16, 2022

36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022

ACCESS Newswire May 16, 2022

Acasti Pharma CEO to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 16th

ACCESS Newswire May 12, 2022

Acasti Pharma to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on April 28th

GlobeNewswire April 25, 2022

Acasti Pharma (TSXV:ACST) appoints Michael L. Derby to its Board of Directors

Brieanna McCutcheon  March 25, 2022

Acasti Pharma Appoints Healthcare Industry Leader Michael L. Derby to its Board of Directors

GlobeNewswire March 25, 2022

Acasti Pharma (TSXV:ACST) receives three international patents for its drug candidates

Caroline Egan  March 22, 2022

Acasti Pharma Announces Patents for GTX-104 in Europe, GTX-102 in the U.S. and GTX-101 in Japan

GlobeNewswire March 22, 2022

Acasti Pharma CEO to Present at the 32nd Annual Oppenheimer Healthcare Conference on March 16th

GlobeNewswire March 9, 2022

Acasti Pharma Celebrates Rare Disease Day

GlobeNewswire February 28, 2022

Acasti Pharma Inc. CEO, Jan D'Alvise, Is Featured on The Stock Day Podcast

Newsfile February 22, 2022

Podcasts